"Pulmatrix has the potential to transform patient care in respiratory disease. In addition to Pulmazole beginning Phase 2, we look forward to advancing PUR1800 towards the clinic. We have a robust pipeline where each product has the potential to positively impact patient lives." said Ted Raad, Pulmatrix's President and Chief Executive Officer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.